Personalized dosing of azacytidine for patients with blood cancers
Official title: Involvement of CDA and/or dCK Metabolizing Enzymes in the Response to Azacytidine Treatment of Patients With Hematologic Malignancies
Run by Assistance Publique Hopitaux De Marseille · NCT06886425 · Data updated 2026-11-12
This study is testing if adjusting the dose of azacytidine based on patients' genetic information can help people with blood cancers like acute myeloid leukemia and myelodysplastic syndromes get better results with fewer side effects.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 70 (estimated) |
| Sponsor | Assistance Publique Hopitaux De Marseille Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Marseille) |
| Status | Recruiting |
| Started | June 14, 2021 |
| Main results expected | January 1, 2027 |
| Study ends | June 14, 2028 |
| Registry record updated | October 28, 2026 |
| Trial ID | NCT06886425 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults over 18 with a diagnosis of acute myeloid leukemia or myelodysplastic syndrome who can provide consent for genetic analysis.
✕Probably not a fit
Patients who are pregnant, under guardianship, or currently participating in another research project may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to personalize the dosing of azacytidine, a standard treatment for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), based on individual pharmacogenetic data. Currently, doses are adjusted after observing toxicity, but this study proposes to adjust doses beforehand to optimize treatment efficacy. Patients will undergo genetic and pharmacokinetic assessments to tailor their azacytidine dosage. The goal is to improve treatment outcomes by minimizing side effects and enhancing therapeutic effectiveness.
Why it matters
Potential benefit: If successful, this approach could lead to more effective and safer treatment regimens for patients with AML and MDS.
How similar studies have gone: While personalized medicine in oncology is a growing field, this specific approach to dose adjustment based on pharmacogenetics is novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients over 18 years of age * Patients with acute myeloid leukemia * Patient with myelodysplastic syndrome * Person who has given non-opposition * Patient who has signed an authorization to perform a constitutional genetic analysis (in the context of care) * Need for effective contraception in patients of childbearing age Exclusion Criteria: * Failure to obtain non-opposition * Adults under guardianship or safeguard of justice * Persons deprived of their liberty * Patient participating in another research project * Pregnancy in progress
Where it's running
-
Hôpital de la Conception
Marseille, France Recruiting
Study contacts
- Study coordinator: Geoffroy Venton
- Email: GEOFFROY.VENTON@ap-hm.fr
- Phone: 0491435817
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Asia MDS Registry: Real-world Insights from Asia
This registry collects real-world data on adults with myelodysplastic syndromes in Asia to see how they are diagnosed, treated, and what outcomes they experience.
-
Optimizing post-transplant bendamustine plus cyclophosphamide for high‑risk myeloid cancers with a partially mismatched donor
This trial tests whether giving bendamustine plus cyclophosphamide after transplant (with possible abatacept or ruxolitinib) can reduce dangerous cytokine release and graft‑versus‑host disease for people with high‑risk myeloid malignancies who have a partially HLA‑mismatched donor.
-
Evaluating the response to a biosimilar treatment for anemia in MDS patients
This study is testing how well a new version of an anemia treatment works for people with Myelodysplastic Syndromes who have either responded to the original treatment before or are starting it for the first time.
-
Combining ICP-248 with Azacitidine for treating Acute Myelogenous Leukemia
This study is testing whether a new drug called ICP-248, when combined with azacitidine, can safely help people with Acute Myelogenous Leukemia feel better and improve their treatment outcomes.
-
Treatment for Myelodysplastic Syndromes with IDH1 Mutation
This study is testing whether a new drug called ivosidenib can help people with myelodysplastic syndromes and an IDH1 mutation feel better compared to the standard treatment with azacitidine.
-
Using Darzalex Faspro to lower antibody levels before stem cell transplant
This study is testing if a new treatment called Darzalex Faspro can help lower harmful antibodies in adults so they can safely receive a stem cell transplant for blood cancers.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.